<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115151</url>
  </required_header>
  <id_info>
    <org_study_id>STU 092016-061</org_study_id>
    <nct_id>NCT03115151</nct_id>
  </id_info>
  <brief_title>Epidural and Intravenous Patient-Controlled Analgesia Following Lumbar Spinal Fusion Surgery</brief_title>
  <official_title>A Comparison of Epidural and Intravenous Patient-Controlled Analgesia Following Lumbar Spinal Fusion Surgery: A Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative analgesia following spine surgery is difficult to manage. Current treatment&#xD;
      modalities rely heavily on opioid analgesics with all of the inherent limitations and side&#xD;
      effects. While current best practice focuses on a 'multimodal approach' (i.e. using multiple&#xD;
      different drugs and techniques to control pain after surgery), there is no consensus&#xD;
      regarding which components of this multimodal therapy provide optimal analgesia. This&#xD;
      prospective randomized study will enroll patients undergoing elective Lumbar Spinal Fusion&#xD;
      Surgery at Zale Lipshy University Hospital. The primary objective is to determine the&#xD;
      comparative efficacy of epidural analgesia, as compared with intravenous (IV)&#xD;
      patient-controlled analgesia (PCA), on post-operative analgesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: Prospective study of 58 subjects undergoing elective Lumbar Spinal Fusion (1-3&#xD;
      levels- posterior approach) at UTSW Zale Lipshy University Hospital with:&#xD;
&#xD;
        1. Continuous Lumbar Epidural Analgesia (Patient-Controlled Epidural Analgesia- PCEA&#xD;
           groups)&#xD;
&#xD;
        2. Intravenous Patient-Controlled Analgesia (IV PCA)&#xD;
&#xD;
      Study Interventions - The intervention to be evaluated in this study is epidural analgesia&#xD;
      using an infusion of 0.0625% bupivacaine plus fentanyl 2mcg/ml. The epidural infusion will be&#xD;
      continued until it is appropriate to transition the patient to a regimen of oral pain&#xD;
      medications. Duration of epidural catheter will be 72 hours a postoperatively.&#xD;
&#xD;
      For subjects in the IV PCA group, the intervention will include post-operative IV PCA with&#xD;
      Hydromorphone.&#xD;
&#xD;
      Epidural catheters will be placed by the spine surgeon under direct visualization&#xD;
      intra-operatively prior to closing the surgical incision. Intra-operative epidural catheter&#xD;
      placement by the spine surgeon will typically be done at the upper end of the dural&#xD;
      exposure/laminectomy.&#xD;
&#xD;
      Epidurals will be assessed for efficacy/function in the recovery room post-operatively by the&#xD;
      APS, and then daily on the floor post-operatively (unless contacted by the floor nurse&#xD;
      regarding specific concerns).&#xD;
&#xD;
      Visual analog pain scale (VAS) will be used to evaluate degree of pain at 3, 24, 48, and 72&#xD;
      hours after surgery.&#xD;
&#xD;
      Additionally, both the IV PCA and the epidural PCEA groups may be given additional &quot;rescue&quot;&#xD;
      pain medications as needed in the recovery room, and these may be continued through the&#xD;
      post-operative period on the floor.&#xD;
&#xD;
      Total study duration is approximately 50 days, which starts from operating room admission for&#xD;
      spinal fusion surgery to the first follow-up visit after discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2017</start_date>
  <completion_date type="Anticipated">December 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 12, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Pain Score (VAS)</measure>
    <time_frame>Postoperative VAS score at 24 hours</time_frame>
    <description>Postoperative Visual Analog Pain Score following lumbar fusion surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total opioid consumption</measure>
    <time_frame>Postoperative the first 24 hours</time_frame>
    <description>Postoperative opioid consumption</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Patient-Controlled Epidural Analgesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupivacaine and fentanyl infusion via Continuous Lumbar Epidural Analgesia during postoperative 72 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous patient-controlled analgesia</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Postoperative intravenous patient-controlled analgesia (IV PCA) with Hydromorphone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Bupivacaine (0.0625%) will be combined with fentanyl for postoperative epidural analgesia via a lumbar epidural catheter</description>
    <arm_group_label>Patient-Controlled Epidural Analgesia</arm_group_label>
    <other_name>Bupivacaine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <description>Hydromorphone will be given continuous infusion for intravenous patient controlled analgesia (syringe 25 mg/50 mL).</description>
    <arm_group_label>Intravenous patient-controlled analgesia</arm_group_label>
    <other_name>DILAUDID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Fentanyl (2 mcg/ml) will be given via epidural route together with bupivacaine.</description>
    <arm_group_label>Patient-Controlled Epidural Analgesia</arm_group_label>
    <other_name>Opioid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subjects aged 18 years or older&#xD;
&#xD;
          -  Scheduled for elective posterior lumbar spinal fusion surgery between 1 and 3 levels&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Baseline cognitive deficits sufficient to make objective pain self-assessments&#xD;
             unreliable in the estimation of the Study Investigators.&#xD;
&#xD;
          -  Immunocompromised subject&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Severe liver and renal dysfunction&#xD;
&#xD;
          -  Preoperative neurological deficits&#xD;
&#xD;
          -  The dura damage during surgery&#xD;
&#xD;
          -  Inability to follow directions or comprehend the English language.&#xD;
&#xD;
          -  Females who are pregnant as determined by positive pregnancy test on or before the day&#xD;
             of surgery.&#xD;
&#xD;
          -  Prisoners.&#xD;
&#xD;
          -  Patient refusal to provide informed consent.&#xD;
&#xD;
          -  Allergy to amide local anesthetics (lidocaine, bupivacaine, ropivacaine) or opioid&#xD;
             (fentanyl) allergy if patient assigned epidural analgesia.&#xD;
&#xD;
          -  Hydromorphone allergy if patient assigned IV PCA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enas Kandil, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enas Kandil, MD</last_name>
    <phone>214/648-9374</phone>
    <email>Enas.Kandil@UTSouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emily Melikman, RN</last_name>
    <phone>214-645-7011</phone>
    <email>Emily.Melikman@utsouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enas Kandil, MD</last_name>
      <phone>214-648-9374</phone>
      <email>Enas.Kandil@UTSouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Texas Southwestern Medical Center, Zale University Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David McDonagh, MD</last_name>
      <phone>214-648-8083</phone>
      <email>David.Mcdonagh@UTSouthwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Enas Kandil</investigator_full_name>
    <investigator_title>ASSOC PROFESSOR - Anesthesiology &amp; Pain Mgmt</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

